A Phase 2/3 interventional study of GLASSIA and methylprednisolone or equivalent steroid in Graft Versus Host Disease, sponsored by Baxalta now part of Shire. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-13.
Sponsored by Baxalta now part of Shire (part of Takeda) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 454 studies in Graft vs Host Disease with a site in United States — 50 open to participants now, 71 under way, 2 of them phase 3. Graft vs Host Disease · United States.
Among the 454 studies in Graft vs Host Disease with a site in United States, this one is the 357th largest by enrollment of the 389 interventional ones that give a count, is one of 17 that started in 2017, is one of 8 in phase 2/3, and was the 316th registered.
804 studies on the registry are indexed under Graft vs Host Disease; 149 are open to participants now.
Browse Graft vs Host Disease studies →50 of the 454 studies in Graft vs Host Disease with a site in United States are open now. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 7+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Regenerative Ocular Immunobiologics LLC · Sites in United States
Ages 18+
Northwell Health · Sites in United States
Ages 18+
Sawa Ito, MD · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 103 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 42 (41%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
454 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 145 · Phase 2 227 · Phase 3 48 · Phase 4 5
First in 1986; this study’s year is marked. 17 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1 is below the median of 35 across 639 interventional studies indexed under Graft vs Host Disease.
Median enrollment 30 across the 389 interventional studies, 81 across the 43 observational. Of the 347 that completed or were terminated, 166 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
80 of 454 have an industry lead sponsor. The 10 most frequent:
This study is registered under Baxalta now part of Shire, one of the names counted as Takeda. Under that name alone:
Baxalta now part of Shire is the lead sponsor of 111 studies on the registry; none are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
Takeda has 2 studies filed under Graft vs Host Disease — fewer than ten, so there is no comparison to draw.
21 of the studies in Graft vs Host Disease with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07776210Phase 3Regenerative Ocular Immunobiologics LLCStudy of d-MAPPS™ Ophthalmic Solution in Adults With Chronic Ocular Graft-Versus-Host Disease (oGVHD) | 2027-03-31 |
| NCT06649201Case Comprehensive Cancer CenterVulvovaginal Graft-versus-Host Disease: Diagnosis and Microbiome Evaluation | 2026-11 |
| NCT05675930Memorial Sloan Kettering Cancer CenterA Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant | 2026-12-22 |
| NCT04044365National Cancer Institute (NCI)Pediatric cGVHD Symptom Scale | 2026-12-31 |
| NCT03533816University of Kansas Medical CenterExpanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide | 2027-01 |
Add all 21 to your calendar (.ics) → With an account.
Among the 454 studies in Graft vs Host Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the safety and efficacy of GLASSIA as an add-on biopharmacotherapy to standard-of-care steroid treatment as the first-line treatment in participants with acute GvHD with lower GI involvement.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants to receive GLASSIA (intravenously) and methylprednisolone or equivalent steroid (either IV or oral per investigator discretion)
Biological: GLASSIA · Drug: methylprednisolone or equivalent steroid
Participants to receive GLASSIA (intravenously) and methylprednisolone or equivalent steroid (either IV or oral per investigator discretion)
Biological: GLASSIA · Drug: methylprednisolone or equivalent steroid
Participants to receive control (intravenously) and methylprednisolone or equivalent steroid (either IV or oral per investigator discretion)
Drug: methylprednisolone or equivalent steroid · Biological: Albumin
GLASSIA \[Alpha1-Proteinase Inhibitor (Human)\]
Also known as: as alpha-1 antitrypsin, A1PI, alpha-1 proteinase inhibitor
The conventional steroid treatment (methylprednisolone or equivalent steroid) will be supplied by the investigators per their institutional practice.
The control vials contain human albumin 20% in 50 mL normal saline solution in glass vials (for non-United States (US) Countries), or Flexbumin 25% in 50 mL in normal saline solution in plastic IV bags (for US).
Also known as: Human Albumin
Percentage of Participants Achieving Overall Response (OR) At Day 28
OR was defined as graft-versus-host disease (GvHD) complete response (CR) + partial response (PR), defined as: - GvHD CR was complete resolution of all signs and symptoms of acute GvHD in all organs without intervening salvage and GvHD PR was improvement of 1 stage in 1 or more organs involved in GvHD without progression in other organs.
Time frame: Day 28
Percentage of Participants Achieving Gastrointestinal (GI) Response at Day 28
GI response was defined as complete response (CR) + partial response (PR), defined as: - GI CR was able to eat; not requiring parenteral nutrition, and passing primarily formed stools - GI PR was decrease in need for parenteral nutrition to less than or equal to (\<=) 50% of required calories; and reduction of stool volume by greater than or equal to (\>=) 50%, without ileus.
Time frame: Day 28
Percentage of Participants Achieving Overall Response at Day 56
Overall response was defined as graft-versus-host disease (GvHD) complete response (CR) + partial response (PR), defined as: - GvHD CR was complete resolution of all signs and symptoms of acute GvHD in all organs without intervening salvage - GvHD PR was improvement of 1 stage in 1 or more organs involved in GvHD without progression in other organs.
Time frame: Day 56
Acute Graft-versus-host Disease (GvHD) Grading at Days 28, 56 and 180
Grading of GvHD was performed by the investigator according to the modified International Bone Marrow Transplant Registry (IBMTR) grading system which classifies the degree of involvement of each organ system by stage on a scale of 0 to 4. The degree of skin involvement was staged depending upon degree and severity of the lesions: Stage 1: Maculopapular rash over less than (\<) 25% of body area, Stage 2: Maculopapular rash over 25 to 50% of body area, Stage 3: Generalized erythroderma, Stage 4: Generalized erythroderma with bullous formation. Degree of GI involvement was staged based on severity of diarrhoea: Stage 1: 500 to 1000 mL/day,Stage 2: 1000 to 1500 mL/day, Stage 3: 1500 to 2000 mL/day, Stage 4: greater than (\>) 2000 mL/day OR pain OR ileus. Degree of liver involvement was staged based upon serum total bilirubin level as follows: Stage 1: 2 to 3 mg/dL, Stage 2: 3 to 6 mg/dL, Stage 3: 6 to 15 mg/dL, Stage 4: \>15 mg/dL.
Time frame: Days 28, 56 and 180
Incidence of Chronic Graft-versus-host Disease (GvHD)
Incidence of chronic GvHD at Days 180 and 365 was reported.
Time frame: Days 180 and 365
Duration of Overall Response (OR)
OR was defined as GvHD CR + PR, defined as: - GvHD CR was complete resolution of all signs and symptoms of acute GvHD in all organs without intervening salvage - GvHD PR was improvement of 1 stage in 1 or more organs involved in GvHD without progression in other organs. Duration of OR was not assessed due to the termination of the study.
Time frame: Baseline up to Day 365
Duration of Gastrointestinal (GI) Response
GI response was defined as CR + PR, defined as: - GI CR was able to eat; not requiring parenteral nutrition, and passing primarily formed stools - GI PR was decrease in need for parenteral nutrition to \<= 50% of required calories; and reduction of stool volume by \>= 50%, without ileus. Duration of GI response was not assessed due to the termination of the study.
Time frame: Baseline up to Day 365
Overall Survival (OS) - Percentage of Participants With an Event
OS was defined as the time from the date of randomization to the date of death due to any cause.
Time frame: Days 100, 180 and 365
Transplant-related Mortality
Transplant-related mortality was determined by the investigator (any deaths considered related to the transplant).
Time frame: Days 28, 56, 100 and 180
Failure-free Survival - Percentage of Participants With an Event
Failure-free survival was defined as the absence of all of the following criteria: Need for second-line treatment for acute GvHD, Non-relapse mortality (death during continuous complete remission) and recurrent malignancy.
Time frame: Days 100 and 180
Graft-versus-host Disease (GvHD)-Free Survival - Percentage of Participants With an Event
GVHD-free survival was defined as being alive without previous onset of acute GVHD or chronic GVHD requiring immunosuppressive therapy.
Time frame: Days 28, 56, 100, 180 and 365
Infection-related Mortality - Percentage of Participants With an Event
Infection-related mortality was determined by the investigator (any deaths considered related to infection \[including infections related to hematopoietic stem cell transplant {HSCT}\]).
Time frame: Days 28, 56, 100 and 180
Graft-versus-host Disease (GvHD)-Related Mortality - Percentage of Participants With an Event
Graft-versus-host disease (GvHD)-related mortality was determined by the investigator (any deaths considered related to GvHD).
Time frame: Days 28, 56, 100 and 180
All-cause Mortality - Percentage of Participants With an Event
All-cause mortality was defined as the time from HSCT to death due to any cause.
Time frame: Days 28, 56, 100 and 180
Number of Participants With Adverse Events (AEs), Treatment-related AEs, Serious Adverse Events (SAEs), Treatment-related SAEs and Temporally-associated AEs
An AE was defined as any untoward medical occurrence in a participant administered an investigational product (IP) that does not necessarily have a causal relationship with the treatment. An SAE was defined as an untoward medical occurrence that at any dose meets one or more of the following criteria: outcome was fatal/results in death, life-threatening, required inpatient hospitalization or resulted in prolongation of an existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event.
Time frame: From start of study drug administration up to 371 days
Number of Participants With Clinically Significant Changes in Clinical Laboratory Assessments
Clinical laboratory assessments such as hematology, clinical chemistry, lipid and coagulation panels and urinalysis were performed.
Time frame: Baseline up to Day 56
Number of Participants With Clinically Significant Changes in Vital Signs
Vital signs included body temperature, respiratory rate, pulse rate and systolic and diastolic blood pressure.
Time frame: Baseline up to Day 56
Number of Participants With Recurrence of Primary Malignancies
Incidence of recurrence of primary malignancies was reported.
Time frame: Baseline up to Day 365
Area Under the Plasma Concentration Curve (AUC0-inf) From Time Zero to Infinity
AUC of GLASSIA was reported.
Time frame: Day 1: through 48 hours; Day 13: through 48 hours; Day 22 and Day 50: through approximately 168 hours
Area Under the Plasma Concentration Curve From Time Zero to Time "t" AUC(0-t) of GLASSIA
AUC(0-t) of GLASSIA was reported.
Time frame: Day 1: through 48 hours, Day 13: through 48 hours, Day 22 and Day 50: through approximately 168 hours
Systemic Clearance at Steady State (CLss) of GLASSIA
CLss of GLASSIA was reported.
Time frame: Day 1: through 48 hours, Day 13: through 48 hours, Day 22 and Day 50: through approximately 168 hours
Maximum Observed Plasma Concentration (Cmax) of GLASSIA
Cmax of GLASSIA was reported.
Time frame: Day 1: through 48 hours, Day 13: through 48 hours, Day 22 and Day 50: through approximately 168 hours
Apparent Volume of Distribution at Steady State (Vss) of GLASSIA
Vss of GLASSIA was reported.
Time frame: Day 1: through 48 hours, Day 13: through 48 hours, Day 22 and Day 50: through approximately 168 hours
Apparent Terminal Half-life (t1/2) of GLASSIA
Apparent terminal half-life (hour), determined as ln2/lambda-z. lambda-z is the apparent terminal rate constant (one per hour), determined by linear regression of the terminal points of the log-linear concentration-time curve. Visual assessment will be used to identify the terminal linear phase of the concentration-time profile. A minimum of 3 data points will be used for determination. t1/2 of GLASSIA was reported.
Time frame: Day 1: through 48 hours, Day 13: through 48 hours, Day 22 and Day 50: through approximately 168 hours
Mean Residence Time (MRT) of GLASSIA
MRT of GLASSIA was not calculated.
Time frame: Day 1: through 48 hours, Day 13: through 48 hours, Day 22 and Day 50: through approximately 168 hours
Trough Plasma Concentration at Steady State (Ctrough) of GLASSIA
Ctrough of GLASSIA was not assessed due to the termination of the study.
Time frame: Day 1: through 48 hours, Day 13: through 48 hours, Day 22 and Day 50: through approximately 168 hours
Study was conducted between 26 April 2017 (first participant first visit) and 03 May 2018 (last participant last visit).
| Milestone | GLASSIA |
|---|---|
| Started | 1 |
| Completed | 1 |
| Not completed | 0 |
OR was defined as graft-versus-host disease (GvHD) complete response (CR) + partial response (PR), defined as: - GvHD CR was complete resolution of all signs and symptoms of acute GvHD in all organs without intervening salvage and GvHD PR was improvement of 1 stage in 1 or more organs involved in GvHD without progression in other organs.
| Percentage of participants | GLASSIA |
|---|---|
| Percentage of Participants Achieving Overall Response (OR) At Day 28 | 100 |
GI response was defined as complete response (CR) + partial response (PR), defined as: - GI CR was able to eat; not requiring parenteral nutrition, and passing primarily formed stools - GI PR was decrease in need for parenteral nutrition to less than or equal to (\<=) 50% of required calories; and reduction of stool volume by greater than or equal to (\>=) 50%, without ileus.
| Percentage of participants | GLASSIA |
|---|---|
| Percentage of Participants Achieving Gastrointestinal (GI) Response at Day 28 | 100 |
Overall response was defined as graft-versus-host disease (GvHD) complete response (CR) + partial response (PR), defined as: - GvHD CR was complete resolution of all signs and symptoms of acute GvHD in all organs without intervening salvage - GvHD PR was improvement of 1 stage in 1 or more organs involved in GvHD without progression in other organs.
| Percentage of participants | GLASSIA |
|---|---|
| Percentage of Participants Achieving Overall Response at Day 56 | 100 |
Grading of GvHD was performed by the investigator according to the modified International Bone Marrow Transplant Registry (IBMTR) grading system which classifies the degree of involvement of each organ system by stage on a scale of 0 to 4. The degree of skin involvement was staged depending upon degree and severity of the lesions: Stage 1: Maculopapular rash over less than (\<) 25% of body area, Stage 2: Maculopapular rash over 25 to 50% of body area, Stage 3: Generalized erythroderma, Stage 4: Generalized erythroderma with bullous formation. Degree of GI involvement was staged based on severity of diarrhoea: Stage 1: 500 to 1000 mL/day,Stage 2: 1000 to 1500 mL/day, Stage 3: 1500 to 2000 mL/day, Stage 4: greater than (\>) 2000 mL/day OR pain OR ileus. Degree of liver involvement was staged based upon serum total bilirubin level as follows: Stage 1: 2 to 3 mg/dL, Stage 2: 3 to 6 mg/dL, Stage 3: 6 to 15 mg/dL, Stage 4: \>15 mg/dL.
| Participants | GLASSIA |
|---|---|
| Day 28: Degree of skin Involvement — Stage 0 | 1 |
| Day 28: Degree of skin Involvement — Stage 1 | 0 |
| Day 28: Degree of skin Involvement — Stage 2 | 0 |
| Day 28: Degree of skin Involvement — Stage 3 | 0 |
| Day 28: Degree of skin Involvement — Stage 4 | 0 |
| Day 28: Degree of GI Involvement — Stage 0 | 1 |
| Day 28: Degree of GI Involvement — Stage 1 | 0 |
| Day 28: Degree of GI Involvement — Stage 2 | 0 |
| Day 28: Degree of GI Involvement — Stage 3 | 0 |
| Day 28: Degree of GI Involvement — Stage 4 | 0 |
| Day 28: Degree of liver Involvement — Stage 0 | 1 |
| Day 28: Degree of liver Involvement — Stage 1 | 0 |
| Day 28: Degree of liver Involvement — Stage 2 | 0 |
| Day 28: Degree of liver Involvement — Stage 3 | 0 |
| Day 28: Degree of liver Involvement — Stage 4 | 0 |
| Day 56: Degree of skin Involvement — Stage 0 | 1 |
| Day 56: Degree of skin Involvement — Stage 1 | 0 |
| Day 56: Degree of skin Involvement — Stage 2 | 0 |
| Day 56: Degree of skin Involvement — Stage 3 | 0 |
| Day 56: Degree of skin Involvement — Stage 4 | 0 |
| Day 56: Degree of GI Involvement — Stage 0 | 1 |
| Day 56: Degree of GI Involvement — Stage 1 | 0 |
| Day 56: Degree of GI Involvement — Stage 2 | 0 |
| Day 56: Degree of GI Involvement — Stage 3 | 0 |
| Day 56: Degree of GI Involvement — Stage 4 | 0 |
| Day 56: Degree of liver Involvement — Stage 0 | 1 |
| Day 56: Degree of liver Involvement — Stage 1 | 0 |
| Day 56: Degree of liver Involvement — Stage 2 | 0 |
| Day 56: Degree of liver Involvement — Stage 3 | 0 |
| Day 56: Degree of liver Involvement — Stage 4 | 0 |
| Day 180: Degree of skin Involvement — Stage 0 | 1 |
| Day 180: Degree of skin Involvement — Stage 1 | 0 |
| Day 180: Degree of skin Involvement — Stage 2 | 0 |
| Day 180: Degree of skin Involvement — Stage 3 | 0 |
| Day 180: Degree of skin Involvement — Stage 4 | 0 |
| Day 180: Degree of GI Involvement — Stage 0 | 1 |
| Day 180: Degree of GI Involvement — Stage 1 | 0 |
| Day 180: Degree of GI Involvement — Stage 2 | 0 |
| Day 180: Degree of GI Involvement — Stage 3 | 0 |
| Day 180: Degree of GI Involvement — Stage 4 | 0 |
| Day 180: Degree of liver Involvement — Stage 0 | 1 |
| Day 180: Degree of liver Involvement — Stage 1 | 0 |
| Day 180: Degree of liver Involvement — Stage 2 | 0 |
| Day 180: Degree of liver Involvement — Stage 3 | 0 |
| Day 180: Degree of liver Involvement — Stage 4 | 0 |
Incidence of chronic GvHD at Days 180 and 365 was reported.
| Participants | GLASSIA |
|---|---|
| Day 180 | 0 |
| Day 365 | 0 |
OR was defined as GvHD CR + PR, defined as: - GvHD CR was complete resolution of all signs and symptoms of acute GvHD in all organs without intervening salvage - GvHD PR was improvement of 1 stage in 1 or more organs involved in GvHD without progression in other organs. Duration of OR was not assessed due to the termination of the study.
No measurements were reported for this outcome.
GI response was defined as CR + PR, defined as: - GI CR was able to eat; not requiring parenteral nutrition, and passing primarily formed stools - GI PR was decrease in need for parenteral nutrition to \<= 50% of required calories; and reduction of stool volume by \>= 50%, without ileus. Duration of GI response was not assessed due to the termination of the study.
No measurements were reported for this outcome.
OS was defined as the time from the date of randomization to the date of death due to any cause.
| Percentage of participants | GLASSIA |
|---|---|
| Day 100 | NA |
| Day 180 | NA |
| Day 365 | NA |
Transplant-related mortality was determined by the investigator (any deaths considered related to the transplant).
| Participants | GLASSIA |
|---|---|
| Day 28 | 0 |
| Day 56 | 0 |
| Day 100 | 0 |
| Day 180 | 0 |
Failure-free survival was defined as the absence of all of the following criteria: Need for second-line treatment for acute GvHD, Non-relapse mortality (death during continuous complete remission) and recurrent malignancy.
| Percentage of participants | GLASSIA |
|---|---|
| Day 100 | 100 |
| Day 180 | 100 |
GVHD-free survival was defined as being alive without previous onset of acute GVHD or chronic GVHD requiring immunosuppressive therapy.
| Percentage of participants | GLASSIA |
|---|---|
| Day 28 | 100 |
| Day 56 | 100 |
| Day 100 | 100 |
| Day 180 | 100 |
| Day 365 | 100 |
Infection-related mortality was determined by the investigator (any deaths considered related to infection \[including infections related to hematopoietic stem cell transplant {HSCT}\]).
| Percentage of participants | GLASSIA |
|---|---|
| Day 28 | 0 |
| Day 56 | 0 |
| Day 100 | 0 |
| Day180 | 0 |
Graft-versus-host disease (GvHD)-related mortality was determined by the investigator (any deaths considered related to GvHD).
| Percentage of participants | GLASSIA |
|---|---|
| Day 28 | 0 |
| Day 56 | 0 |
| Day 100 | 0 |
| Day 180 | 0 |
All-cause mortality was defined as the time from HSCT to death due to any cause.
| Percentage of participants | GLASSIA |
|---|---|
| Day 28 | 0 |
| Day 56 | 0 |
| Day 100 | 0 |
| Day180 | 0 |
An AE was defined as any untoward medical occurrence in a participant administered an investigational product (IP) that does not necessarily have a causal relationship with the treatment. An SAE was defined as an untoward medical occurrence that at any dose meets one or more of the following criteria: outcome was fatal/results in death, life-threatening, required inpatient hospitalization or resulted in prolongation of an existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event.
| Participants | GLASSIA |
|---|---|
| Any Adverse Event | 1 |
| Treatment-related AEs | 0 |
| Serious adverse Events (SAEs) | 0 |
| Treatment-related SAEs | 0 |
| Temporally-associated AEs | 0 |
Clinical laboratory assessments such as hematology, clinical chemistry, lipid and coagulation panels and urinalysis were performed.
| Participants | GLASSIA |
|---|---|
| Number of Participants With Clinically Significant Changes in Clinical Laboratory Assessments | 0 |
Vital signs included body temperature, respiratory rate, pulse rate and systolic and diastolic blood pressure.
| Participants | GLASSIA |
|---|---|
| Number of Participants With Clinically Significant Changes in Vital Signs | 0 |
Incidence of recurrence of primary malignancies was reported.
| Participants | GLASSIA |
|---|---|
| Number of Participants With Recurrence of Primary Malignancies | 0 |
AUC of GLASSIA was reported.
| Hour*milligrams per deciliter (h*mg/dL) | GLASSIA: Day 1: 90 mg/kg | GLASSIA: Day 13: 30 mg/kg | GLASSIA: Day 22: 120 mg/kg | GLASSIA: Day 50: 120 mg/kg |
|---|---|---|---|---|
| Area Under the Plasma Concentration Curve (AUC0-inf) From Time Zero to Infinity | 61500 | 43500 | 126000 | 117000 |
AUC(0-t) of GLASSIA was reported.
| h*mg/dL | GLASSIA: Day 1: 90 mg/kg | GLASSIA: Day 13: 30 mg/kg | GLASSIA: Day 22: 120 mg/kg | GLASSIA: Day 50: 120 mg/kg |
|---|---|---|---|---|
| Area Under the Plasma Concentration Curve From Time Zero to Time "t" AUC(0-t) of GLASSIA | 16300 | 11000 | 40400 | 33400 |
CLss of GLASSIA was reported.
| Deciliters per hour (dL/h) | GLASSIA: Day 13: 30 mg/kg | GLASSIA: Day 22: 120 mg/kg | GLASSIA: Day 50: 120 mg/kg |
|---|---|---|---|
| Systemic Clearance at Steady State (CLss) of GLASSIA | 0.297 | 0.286 | 0.260 |
Cmax of GLASSIA was reported.
| Milligrams per deciliter (mg/dl) | GLASSIA: Day 1: 90 mg/kg | GLASSIA: Day 13: 30 mg/kg | GLASSIA: Day 22: 120 mg/kg | GLASSIA: Day 50: 120 mg/kg |
|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of GLASSIA | 339 | 262 | 390 | 409 |
Vss of GLASSIA was reported.
| Deciliter (dL) | GLASSIA: Day 13: 30 mg/kg | GLASSIA: Day 22: 120 mg/kg | GLASSIA: Day 50: 120 mg/kg |
|---|---|---|---|
| Apparent Volume of Distribution at Steady State (Vss) of GLASSIA | 50.9 | 123 | 91.1 |
Apparent terminal half-life (hour), determined as ln2/lambda-z. lambda-z is the apparent terminal rate constant (one per hour), determined by linear regression of the terminal points of the log-linear concentration-time curve. Visual assessment will be used to identify the terminal linear phase of the concentration-time profile. A minimum of 3 data points will be used for determination. t1/2 of GLASSIA was reported.
| Hour (h) | GLASSIA: Day 1: 90 mg/kg | GLASSIA: Day 13: 30 mg/kg | GLASSIA: Day 22: 120 mg/kg | GLASSIA: Day 50: 120 mg/kg |
|---|---|---|---|---|
| Apparent Terminal Half-life (t1/2) of GLASSIA | 152 | 117 | 317 | 247 |
MRT of GLASSIA was not calculated.
No measurements were reported for this outcome.
Ctrough of GLASSIA was not assessed due to the termination of the study.
No measurements were reported for this outcome.
Collected over From the start of drug administration up to 371 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GLASSIA | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Event | GLASSIA |
|---|---|
| Platelet count decreased/Investigations | 1/1 |
| PruritusSkin and subcutaneous tissue disorders | 1/1 |
| HyperglycaemiaMetabolism and nutrition disorders | 1/1 |
| HypocalcaemiaMetabolism and nutrition disorders | 1/1 |
| Vision blurredEye disorders | 1/1 |
| HypokalaemiaMetabolism and nutrition disorders | 1/1 |
| Weight decreasedInvestigations | 1/1 |
| Blood cholesterol increasedInvestigations | 1/1 |
| HypomagnesaemiaMetabolism and nutrition disorders | 1/1 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/1 |
| Age, Categorical(Participants) | GLASSIA |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 1 |
| >=65 years | 0 |
| Sex: Female, Male(Participants) | GLASSIA |
|---|---|
| Female | 0 |
| Male | 1 |
| Ethnicity (NIH/OMB)(Participants) | GLASSIA |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 1 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | GLASSIA |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 1 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — De-identified individual participant data from this particular study will not be shared as there is a reasonable likelihood that individual patients could be re-identified (due to the low number of study participants).
Ran from Apr 2017 to primary completion in May 2018, 12 months.
Results were first posted in Apr 2019, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alpha 1-Antitrypsin